PFNX stock news

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure Inc (NASDAQ: NXTC ) Pfenex Inc (NYSE: PFNX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 5) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) BioNano Genomics Inc (NASDAQ: BNGO ) Endologix, Inc. (NASDAQ: ELGX ) Mallinckrodt PLC (NYSE: MNK ) ( retreated amid reports of restructuring ahead of Cleveland opioid litigation) Merit Medical Systems, Inc. (NASDAQ: MMSI ) VBI Vaccines Inc (NASDAQ: VBIV ) Zafgen Inc (NASDAQ: ZFGN ) ( announced decision to explore strategic options) See Also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Neon's Process To Predict Neoantigens To Control Tumor Growth Published In Scientific Journal Neon Therapeutics Inc (NASDAQ: NTGN ) announced publication in the scientific journal "Immunity," a breakthrough process for predicting which neoantigens will be presented by MHC Class II molecules in the tumor microenvironment. Read more
Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more

EMA accepts Pfenex's MAA for PF708

01:04pm, Thursday, 30'th May 2019
Read more
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE: PFNX ) and Alvogen today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted by our partner Alvogen for PF708 (teriparatide). The product is proposed as a therapeutic equivalent in the treatment of osteoporosis to Forteo®. The product is filed with the EMA as a biosimilar in the treatment of osteoporosis to Forsteo®, which achieved $289 million sales in the E.U. and $1.6 billion in global product sales in 2018. This acceptance means the EMA considers the MAA to be complete and initiates the EMA's formal review process. "The acceptance of the PF708 MAA filing is an important milestone for Pfenex and Alvogen and demonstrates that through our collaborative partnership, we continue making progress towards potential approvals beyond the United States," said Eef Schimmelpennink, Chief Executive Officer of Pfenex. "Subject to applicable regulatory approvals, for Europe, PF708 will be commercialized by Theramex, a leading global specialty pharmaceutical company dedicated to Women's Health." "We are very pleased with the EMA's acceptance of the MAA for review. Read more
As of late, it has definitely been a great time to be an investor in Pfenex Inc. (PFNX). Read more
Pfenex (PFNX) delivered earnings and revenue surprises of 52.00% and 84.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Read more

Pfenex beats by $0.15, beats on revenue

08:33pm, Thursday, 09'th May 2019
Read more
Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Since Pfenex Inc. (NYSEAMERICAN:PFNX) and Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the p Read more
Since Forty Seven Inc. (NASDAQ:FTSV) and Pfenex Inc. (NYSEAMERICAN:PFNX) are part of the Biotechnology industry, they are influenced by contrast. The Read more
Investors might be trying to step up their game in order to play a more active role with their investments. Investors who keep a close watch on what is happening with their money may be putting themse Read more
We will be contrasting the differences between Pfenex Inc. (NYSEAMERICAN:PFNX) and Novelion Therapeutics Inc. (NASDAQ:NVLN) as far as institutional ownership, analyst recommendations, profitability, r Read more

Proudly made at

ROCKIT